• Rebecca Arend, MD is Assistant Professor and an Associate Scientist at the UAB Comprehensive Cancer Center Experimental Therapeutics Program. She completed her undergraduate degree and her residency at Columbia Presbyterian in New York, NY and completed her fellowship at UAB. Prior to fellowship, she did research in hormonal and molecular pathways associated with uterine carcinosarcoma. During her fellowship in Gyn Oncology at UAB, she received an AAOGF/ABOG Young Investigator Fellowship grant that currently supports her own lab with 75% protected research time. Her on-going projects include personalized medicine, targeting the Wnt pathway, and immunotherapy in ovarian cancer patients. She is getting her Master’s degree (MSPH) in Clinical and Translational Research and serves as the chair of UAB’s Tissue Committee and as the co-chair of the Gynecologic Oncology Disease Oriented Working Group (DOWG) and the Precision Oncology Working Group (POWG). She is a member of multiple professional societies and committees both regionally and nationally. She has authored numerous publications and been highly recognized for outstanding presentations.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 Inhibiting WNT ligand production for improved immune recognition in the Ovarian tumor microenvironment 2020
    2020 EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer 2020
    2020 Large, Non-Cavity Distorting Intramural Leiomyomas Decrease Leukemia Inhibitory Factor in the Secretory Phase Endometrium 2020
    2020 Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: A review 2020
    2020 Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer 2020
    2020 Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect 2020
    2020 Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer 2020
    2019 Biomarkers in ovarian cancer: To be or not to be 2019
    2019 Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1 2019
    2019 Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer 2019
    2019 Neutrophilia and mortality in women with uterine carcinosarcoma 2019
    2019 Advancing drug development in gynecologic malignancies 2019
    2019 Checkpoint inhibitors in ovarian cancer: A review of preclinical data 2019
    2019 A review of the role of wnt in cancer immunomodulation 2019
    2019 Review: Targeting the transforming growth factor-beta pathway in ovarian cancer 2019
    2019 The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth 2019
    2019 Overcoming immune suppression with epigenetic modification in ovarian cancer 2019
    2019 Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics 2019
    2018 The antitumor effects of entinostat in ovarian cancer require adaptive immunity 2018
    2018 Revisiting entinostat as an immune-potentiating adjuvant 2018
    2018 Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm 2018
    2018 FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer 2018
    2018 Disparities in receipt of follow-up care instructions among female adult cancer survivors: Results from a national survey 2018
    2018 Endometrial cancer: Molecular markers and management of advanced stage disease 2018
    2018 Favorable effects of a ketogenic diet on physical function, perceived energy, and food cravings in women with ovarian or endometrial cancer: A randomized, controlled trial 2018
    2018 Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma 2018
    2018 Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer [Oncotarget., 7, (2016) (86803-86815)] 10.18632/oncotarget.13466 2018
    2018 Histone methyltransferase ezh2: A therapeutic target for ovarian cancer 2018
    2018 Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma 2018
    2018 A ketogenic diet reduces central obesity and serum insulin in women with ovarian or endometrial cancer 2018
    2017 Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review 2017
    2017 B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models 2017
    2017 Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth 2017
    2017 Implementation and utilization of the molecular tumor board to guide precision medicine 2017
    2017 Uterine carcinosarcomas: Clinical, histopathologic and immunohistochemical characteristics 2017
    2016 Ovarian cancer and the immune system — The role of targeted therapies 2016
    2016 The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype 2016
    2016 Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974 2016
    2016 Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review 2016
    2016 Niclosamide and its analogs are potent inhibitors of Wnt/ß- catenin, mTOR and STAT3 signaling in ovarian cancer 2016
    2015 PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis 2015
    2015 Niclosamide analogs for treatment of ovarian cancer 2015
    2014 Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival? 2014
    2014 Multi-targeted therapy of cancer by niclosamide: A new application for an old drug 2014
    2014 Effect of niclosamide on basal-like breast cancers 2014
    2014 Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer 2014
    2014 Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma 2014
    2013 The Wnt/β-catenin pathway in ovarian cancer: A review 2013
    2013 Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer 2013
    2012 Failure to rescue as a source of variation in hospital mortality for ovarian cancer 2012
    2011 Uterine carcinosarcoma 2011
    2010 Long-term outcome and natural history of uterine adenosarcomas 2010
    2010 Fertility preservation in ovarian cancer 2010
    2010 Co-expression of GPR30 and ERβ and their association with disease progression in uterine carcinosarcoma 2010
    2009 Extragenital adenosarcoma: A case report, review of the literature, and management discussion 2009
    2009 Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma 2009

    Research Overview

  • Clinical Trials
    Translational Research
    Basic Science Research
    Biomarker Discovery
    Early Detection
    Molecular Targeted Therapy
    Personalized Medicine
    Hereditary Ovarian Cancer Syndrome
  • Principal Investigator On

  • Private Grant  awarded by GOG FOUNDATION INC. 2019 - 2024
  • Private Grant  awarded by TESARO, INC. 2019 - 2024
  • Private Grant  awarded by MERSANA THERAPEUTICS 2020 - 2023
  • Private Grant  awarded by Leap Therapeutics, Inc. 2017 - 2022
  • Improving Immune Response in Ovarian Cancer by Modulating the Wnt Pathway  awarded by DOD - Department of Defense 2018 - 2022
  • UAB 1788: Pilot Study of Daily Exemestane in Women with Complex Alypical Hyperplasia of The Endometrium / Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer (Fixed Price)  awarded by University of Wisconsin-Madison 2017 - 2021
  • UAB 1788; Pilot Study of Daily Exemestane in Women with Complex Alypical Hyperplasia of The Endometrium / Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer (Cost Reimbursable)  awarded by University of Wisconsin-Madison 2017 - 2021
  • Collaboration and Material Transfer Agreement – Ovarian Cancer Specimens  awarded by University of South Alabama 2016 - 2021
  • The Role of TGF-B in Immune Suppression in Suboptimally Debulked Ovarian Cancer Patients  awarded by NATIONAL COMPREHENSIVE CANCER NETWORK 2018 - 2020
  • Private Grant  awarded by EMD SERONO 2019
  • SPORE in Cervical Cancer - Tissue Core  awarded by Johns Hopkins University 2014 - 2019
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS 2017 - 2019
  • Treatment of Ovarian Cancer with WNT/B-Catenin Inhibitors  awarded by American Association of Obstetricians and Gynecologists Foundation 2015 - 2018
  • Priming Anti-Tumor Immunity in Ovarian Cancer With Epigenetics  awarded by Foundation for Women's Cancer 2016 - 2018
  • Using the Genomic Profile of High Intermediate Risk Endometrial Cancer Patients to Differentiate Patients at High Risk of Recurrence from the Majority with Low Risk of Recurrence  awarded by FOUNDATION FOR GYNECOLOGIC ONCOLOGY 2016 - 2017
  • Investigator On

  • Private Grant  awarded by ARCUS BIOSCIENCES INC 2020 - 2025
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2020 - 2025
  • Private Grant  awarded by CORCEPT THERAPEUTICS, INC. 2020 - 2025
  • Private Grant  awarded by ELI LILLY AND COMPANY 2019 - 2024
  • Private Grant  awarded by PUMA BIOTECHNOLOGY, INC. 2019 - 2024
  • Glycosylation-dependent Mechanisms Regulating Ovarian Tumor cell Phenotype  awarded by National Cancer Institute/NIH/DHHS 2019 - 2024
  • Private Grant  awarded by IMMUNOGEN, INC. 2019 - 2024
  • Private Grant  awarded by CELSION CORPORATION 2018 - 2023
  • Private Grant  awarded by SYROS PHARMACEUTICALS INC. 2018 - 2023
  • Private Grant  awarded by GENMAB 2018 - 2023
  • Private Grant  awarded by DECIPHERA PHARMACEUTICALS. LLC 2018 - 2023
  • UAB 1753 A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction with Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer  awarded by University of Chicago 2018 - 2023
  • Private Grant  awarded by TAPIMMUNE, INC. 2018 - 2023
  • Private Grant  awarded by AGENUS, INC. 2020 - 2023
  • Private Grant  awarded by IMMUNOGEN, INC. 2017 - 2022
  • Private Grant  awarded by MedImmune 2019 - 2022
  • Private Grant  awarded by TESARO, INC. 2016 - 2021
  • Neoadjuvant Chemotherapy Tumor Profiling in Ovarian Cancer: Genomic and Proteomic Analysis  awarded by NRG ONCOLOGY FOUNDATION 2016 - 2021
  • Private Grant  awarded by MATEON THERAPEUTICS, INC. 2016 - 2021
  • Overcoming PAAP Inhibitor Resistance of BACA-Deficient Ovarian Cancers  awarded by DOD - Department of Defense 2018 - 2021
  • Private Grant  awarded by PLEXXIKON 2016 - 2021
  • Private Grant  awarded by ABBVIE INC 2015 - 2020
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology 2017 - 2020
  • Private Grant  awarded by CELSION CORPORATION 2015 - 2020
  • Private Grant  awarded by INCYTE CORPORATION 2015 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2018 - 2019
  • Private Grant  awarded by ABBVIE INC 2018 - 2019
  • COMPLETED - SPORE in Cervical Cancer - Project 5  awarded by Johns Hopkins University 2014 - 2019
  • SPORE in Cervical Cancer  awarded by Johns Hopkins University 2014 - 2019
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • Private Grant  awarded by Genentech 2017 - 2019
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2018 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • Private Grant  awarded by LICOR, INC. 2017 - 2019
  • Glycosylation-Dependent Mechanisms Regulating Ovarian Tumor Cell Survival  awarded by National Institute of General Medical Sciences/NIH/DHHS 2014 - 2018
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2016
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2016
  • Prospective Correlation of Multinational Association of Supportive Care of Cancer Risk-Index Score with Management of Gynecologic Oncology Patients with Neutropenic Fever  awarded by University of Oklahoma 2013 - 2015
  • Treatment of Ovarian Cancer with WNT/B-Catenin Inhibitors  awarded by American Association of Obstetricians and Gynecologists Foundation 2015
  • Wnt/ß-catenin Pathway as a Target for the Treatment of Ovarian Cancer  awarded by Foundation for Women's Cancer 2014
  • Education And Training

  • Doctor of Medicine, Yeshiva University 2008
  • Columbia Presbyterian Medical Center, Residency 2012
  • Full Name

  • Rebecca Arend